NCT07207954View on ClinicalTrials.gov

Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

October 6, 2025

Primary Completion Date

July 16, 2027

Study Completion Date

July 16, 2027

Conditions
Rheumatoid Arthritis
Interventions
DRUG

LFD-200

2 mL glass vials, as 150 mg/mL concentrated solution

OTHER

Placebo

0.9% NaCl

DRUG

Oral Prednisone

Tablet

OTHER

Placebo

Placebo tablet to match Prednisone

Trial Locations (7)

112

Arensia Exploratory Medicine LLC, Tbilisi

1135

"ARENSIA EXPLORATORY MEDICINE LIMITED LIABILITY COMPANY, Medical Center, Department of Clinical Trials", Kyiv

3004

Nucleus Network, Melbourne

MD2025

"Clinical Republican Hospital Timofei Mosneaga, ARENSIA E.M.", Chisinau

87-100

MICS Centrum Medyczne Torun - MICS - PPDS, Torun

02-637

National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, Warsaw

02-691

Centrum Medyczne Reuma Park, Warsaw

Sponsors
All Listed Sponsors
lead

Lifordi Immunotherapeutics, Inc.

INDUSTRY